Literature DB >> 15310522

Compliance with nasal CPAP in obstructive sleep apnea patients.

P Collard1, T Pieters, G Aubert, P Delguste, D O Rodenstein.   

Abstract

Continuous positive airway pressure (CPAP) is currently the treatment of choice for the majority of patients with obstructive sleep apnea (OSA). After a CPAP trial, the initial acceptance rate is 70-80%. Patients who derive no subjective benefit from such a trial are poor candidates for home treatment with CPAP because they are likely to exhibit lower adherence and compliance rates. About 90% of OSA patients provided with CPAP apparatus will adhere to long-term CPAP treatment. Patients abandoning CPAP do so during the first few months of home therapy, a period during which close monitoring and support is warranted. Because of the strong correlation between the machine run time and effective pressure delivered at the nasal mask (90-95%), the time-counter of the CPAP device is sufficient to monitor compliance in clinical practice, allowing for early intervention in cases of suboptimal use. Longterm acceptors of CPAP display a satisfactory compliance (5-6.5 h of average daily use) which compares favourably with compliance with treatment in other chronic diseases. Lower acceptance and compliance rates have been reported in North America as compared to Europe. This could be related to cultural differences or different routines of prescription and follow-up.

Entities:  

Year:  1997        PMID: 15310522     DOI: 10.1016/s1087-0792(97)90004-6

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  30 in total

1.  Improvement of CPAP Therapy by a Self-Adjusting System.

Authors:  Katrin Pilz; Stefan Thalhofer; Philipp Meissner; Peter Dorow
Journal:  Sleep Breath       Date:  2000       Impact factor: 2.816

2.  A critical evaluation of surgery for sleep disordered breathing.

Authors:  Boris A Stuck
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2006-10-05

3.  The Sleep Apnea cardioVascular Endpoints (SAVE) Trial: Rationale, Ethics, Design, and Progress.

Authors:  Nick A Antic; Emma Heeley; Craig S Anderson; Yuanming Luo; Jiguang Wang; Bruce Neal; Ron Grunstein; Ferran Barbe; Geraldo Lorenzi-Filho; Shaoguang Huang; Susan Redline; Nanshan Zhong; R Doug McEvoy
Journal:  Sleep       Date:  2015-08-01       Impact factor: 5.849

4.  Insomnia symptoms influence CPAP compliance.

Authors:  Christoph Pieh; Magdalena Bach; Roland Popp; Cecilia Jara; Tatjana Crönlein; Göran Hajak; Peter Geisler
Journal:  Sleep Breath       Date:  2012-02-04       Impact factor: 2.816

5.  Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure in the treatment of Cheyne-Stokes respiration in heart failure over a six month period.

Authors:  C Philippe; M Stoïca-Herman; X Drouot; B Raffestin; P Escourrou; L Hittinger; P-L Michel; S Rouault; M-P d'Ortho
Journal:  Heart       Date:  2005-06-17       Impact factor: 5.994

6.  Reliable calculation of the efficacy of non-surgical and surgical treatment of obstructive sleep apnea revisited.

Authors:  M J L Ravesloot; N de Vries
Journal:  Sleep       Date:  2011-01-01       Impact factor: 5.849

7.  Cues to starting CPAP in obstructive sleep apnea: development and validation of the cues to CPAP Use Questionnaire.

Authors:  Sara Olsen; Simon Smith; Tian P S Oei; James Douglas
Journal:  J Clin Sleep Med       Date:  2010-06-15       Impact factor: 4.062

8.  Factors affecting the intention and decision to be treated for obstructive sleep apnea disorder.

Authors:  Shosh Shahrabani; Orna Tzischinsky; Gili Givati; Yaron Dagan
Journal:  Sleep Breath       Date:  2014-02-27       Impact factor: 2.816

9.  Modafinil in the treatment of excessive sleepiness.

Authors:  Jonathan R L Schwartz
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

10.  Initial adherence to autotitrating positive airway pressure therapy: influence of upper airway narrowing.

Authors:  Yoon Kyoung So; Hun-Jong Dhong; Hyo Yeol Kim; Seung-Kyu Chung; Jeon-Yeob Jang
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-12-31       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.